Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Marketing, Pricing Practices Lead To Settlement With Justice Dept.

Executive Summary

Merck's $650 million settlement with the Department of Justice to resolve state and federal investigations into payment of Medicaid rebates and incentives to health care workers will act as a deterrent to other drug makers, the agency said

You may also be interested in...



Vioxx Settlement Down, Merck Has Three More Government Probes Pending

Sales rep call notes on Vioxx off-label promotion were a key part of the government’s criminal case against Merck; $950 million settlement includes a new corporate integrity agreement that requires monitoring of call notes.

Another Vioxx Settlement, Another Must-Do List For Merck

Merck has settled Vioxx shareholder derivative litigation by agreeing to implement a host of corporate governance changes. Among the new requirements, Merck must run ads in medical journals publicizing its clinical trial registry, post reviews of its compliance procedures, and create two safety committees

Another Vioxx Settlement, Another Must-Do List For Merck

Merck has settled Vioxx shareholder derivative litigation by agreeing to implement a host of corporate governance changes. Among the new requirements, Merck must run ads in medical journals publicizing its clinical trial registry, post reviews of its compliance procedures, and create two safety committees

Related Content

UsernamePublicRestriction

Register

PS049291

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel